On Demand 2024 Sunday PM General Sessions

This collection covers general sessions from Sunday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Updates on Vaccines: What the Allergist Needs to Know
  • Staying Informed With ABAI
  • And the Worst Virus Associated with Asthma Is...?
  • Dermatology Jeopardy! What is this Rash?
  • Social Media and Podcasting: The Changing Face of Medical Education
  • The Multiple Facets of Non-IgE Milk Allergy
  • AACA: Evaluation and Treatment of Antibody Deficiencies Attributable to Inborn Errors of Immunity
  • The Role of Genetic Testing in Managing Immunodeficiency

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 11.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Analyze the current vaccine recommendation schedule and changes that impact clinical care.
  • Update on vaccine use in Immunocompromised patients including indications, contraindications, and prophylaxis.
  • Tools to address vaccine hesitancy in practice and effective communication with patients.
  • Gain insight of ABMS opportunities that are available.
  • Characterize the responsibilities, dedication and commitment of an ABAI Director.
  • Identify the development/timeline of a CAP Block.
  • Review the impact of early-life and adult RSV infections and its effects on asthma.
  • Discuss the impact of rhinovirus on the development and exacerbation of asthma.
  • Evaluate the roles of coronaviruses, human metapneumovirus and bocavirus in asthma pathogenesis and exacerbations.
  • Define basic dermatology terms.
  • Differentiate between skin lesions that have a similar appearance.
  • Develop appropriate treatment plans.
  • Recognize the many ways that medical education is changing for both the provider and patient. Realize the potential legal ramifications of using social media as an allergist.
  • Use social media for medical education.
  • Develop a plan to participate in social media.
  • Recognize the diagnosis and management of allergic proctocolitis in the allergy clinic. Describe milk FPIES presentation, diagnosis and management, including when to perform an OFC and which dietary restrictions to follow.
  • Master the diagnosis and management of milk triggered EOE.
  • Discern the appropriate use of formulas for different non-IgE milk allergy conditions, risk of malnutrition and evaluation of growth in the allergy clinic.
  • Discuss the burden of illness attributable to antibody deficiencies.
  • Develop a diagnostic work-up for patients presenting with suspected antibody deficiencies.
  • Identify novel treatment strategies for patients with antibody deficiencies attributable to inborn errors of immunity. Utilize shared decision-making in therapeutic considerations for the treatment of antibody deficiencies.
  • Recognize the clinical allergist/immunologist needs to remember about genetic basics.
  • Identify the tools needed to review a VUS.
  • Provide examples of genetic testing, management and treatment of immunodeficiency.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 11.75 AMA PRA Category 1 Credit™
  • 11.75 Attendance
  • 11.75 CBRN
Course opens: 
11/11/2024
Course expires: 
11/10/2027
Part of: 
On Demand ACAAI 2024 Annual Scientific Meeting General Sessions
Rating: 
0

Karla Adams, MD. FACAAI
Sangeetha M. Kodoth, MD, FACAAI
James M. Quinn, MD, FACAAI
Niraj C. Patel, MD, MS, FACAAI
Dipa K. Sheth, MD, FACAAI
Michael R. Nelson, MD, PhD, FACAAI
Mitchell R. Lester, MD, FACAAI
Theodore M. Freeman, MD, FACAAI
Angela D. Hogan, MD, FACAAI
Clinton P. Dunn, MD
Mitchell H. Grayson, MD, FACAAI
James E. Gern, MD
Joshua L. Kennedy, MD
David R. Stukus, MD, FACAAI
Theresa A. Bingemann, MD, FACAAI
Stephanie L. Mawhirt, DO, FACAAI
Gil Yosipovitch, MD
Douglas H. Jones, MD, FACAAI
Mechelle Arin Vazquez, MD
Manisha Relan, MD, FACAAI
Farah Nawaz Khan, MD
Zachary E. Rubin, MD, FACAAI
Payel Gupta, MD, FACAAI
Joyce Elaine Yu, MD, FACAAI
Nicole E. Barberis, MD
Krishan D. Chhiba, MD, PhD
Shyam R. Joshi, MD
Anna H. Nowak-Wegrzyn, MD, PhD, FACAAI
Justin C. Greiwe, MD, FACAAI
Marion E. Groetch, RDN
Russell A. Settipane, MD, MD, FACAAI
Sandra M. Gawchik, DO, FACAAI
Richard L. Wasserman, MD, PhD, FACAAI
Antoine E. Azar, MD
Catherine Freeman, MD
Mark M. Ballow, MD, FACAAI
Myron J. Zitt, MD, FACAAI
Annette F. Carlisle, MD
Jolan Walter, MD, PhD
Benjamin Prince, MD, FACAAI
Ivan Chinn, MD

Available Credit

  • 11.75 AMA PRA Category 1 Credit™
  • 11.75 Attendance
  • 11.75 CBRN
Please login or create an account to take this course.